We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

June 21, 2019

Why You Should be Excited about our Q2 Report: Digital Health Evidence Review 2019

Commentary
Chandana Fitzgerald
&


The growing number of digital health companies that have reached unicorn status in the past two years would lead many to believe that this has finally become a mature, well established space. However, when it comes to the application of digital health in real world clinical settings, we still have a long way to go.


We have some unforgettable examples in the archives to prove growth hacks are not sustainable in healthcare. Aggressiveness for disruption by softwares in other industries cannot be replicated in healthcare. We need to take the time to establish a solid evidence base to support their claims before going gung-ho with the marketing and partnerships.


Given that the environment in which these digital health technologies are being funded and developed is not comparable to that in which pharmaceuticals are being developed, we are walking into our report and analysis with the assumption that there is not as much evidence out there in terms of rigor, size, validated endpoints, validated digital trial protocol, validated placebo, widespread geography, but are open to being proven wrong.


HealthXLs Digital Health Evidence Review 2019. This report aims to identify, categorize, and summarize all existing, relevant studies in digital health. Through this report, we want to establish a clear understanding of the existing body of clinical evidence for digital health, its maturity, current gaps and needs.


Hypothesis - What do we expect to find in the universe of digital health publications?

Some of the hypotheses we are gunning to decode this report include the following:



Methodology - What’s driving the data?

The HealthXL Research and Platform teams have joined forces to collate thousands of digital health related publications in order to decode our hypothesis and uncover hidden insights - we are using a number of digital and clinical terms to slice the Everest of information we have at hand. Here is an overview of some of the sources we will be pulling from to access this information.


Q2 Report incorporates research data from:


In addition to the research collected we will be cross referencing other data points including:



In addition to the data insights gathered, we will be nuancing our findings with expert input from clinicians, investors and industry executives and triangulating with our own insights gathered from the thousands of hours of digital health research we already have under our belts.



User Stories - What value will these insights provide and to whom?


Throughout this report are peppered user stories - you will probably be able to associate with one or more. Below is how we intend to answer and address these user stories through our investigation.


User Story 1 - As a HealthXL member, I want to be able to see if digital health solutions are producing the same rigor of evidence as drugs, and if money going into the sector matches evidence generation and subsequent regulatory approval and commercial partnerships.


This will involve mapping HealthXLs research data with data on investment, IP, regulatory status, commercial partnerships, location.



User Story 2 - As a Therapeutic Area (TA) head, I want to understand a snapshot of my TA maturity in the form of published evidence for digital solutions.


Fields of Study -

Digital Areas: We want to identify the digital areas with the most evidence generated to date - is it telemedicine, or mHealth, or Digital Therapeutics? It may help answer the elusive question of maturity, and help us understand, as an industry, which areas are more ripe for adoption.


Therapeutic Areas: As a first step, we have identified the top disease areas by burden, globally.


What we are now attempting to do is map the digital studies captured above, to these areas by burden and identify commonalities or gaps. Shouldn’t new solutions address conditions that have the greatest morbidity and mortality to really help populations live healthier and longer?


User Story 3 - As a Senior Healthcare Executive, I want to be able to understand who the front-runners are for running research in digital health (universities, hospitals and start-ups), who are worth their dime in proving their technology, efficacy and efficiency.


Centers of Study -

We will map the digital studies captured back to the academic or research centers and hospitals where they have been conducted. This will not only tell us who the most active researchers are in digital health, but also help us identify hubs and hotspots for innovation in health technology. We will map this to university/ hospital and also to geographical region. Looking for your next big investment or partnerships - you will know where the foundations are being laid!


Journals of Reverence -

We all know of the gurus of medical and scientific journals - the Natures and NEJMs of the world. What we’d like to see is how many of these journals are publishing studies on digital health. If studies and trials in this space are not featured in these hallowed journals, it is very likely that they will not grab the attention of the scientific community. We want to call out this gap, if it exists.



User Story 4 - As a pharma innovator/ strategic investor,  I want to understand competitive landscape from a clinical evidence perspective to help me make partner decisions.


Correlations -

We will use additional data from the HealthXL platform on digital health companies and identify correlations (if any) between strong clinical evidence and  


We are super excited (and quite overwhelmed) about our Q2 Report (coming this July to your inbox). We want this report to be your reference and guide to mapping digital health studies and generating evidence. We want us, as an industry, to be thinking about what the methodologies should look like when it comes to evaluating digital health innovations, and ultimately inform the creation of validated, robust companies, guidelines and partnerships.


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: How to get your DTx product reimbursed in the US?

4th November @ 11:45AM EDT

Are you a DTx company seeking reimbursement in the US? Then this masterclass is for you. Join us in this US-focused interactive masterclass led by Mike Pace, who will walk us through how to get your DTx product reimbursed in the US.

Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DiGa - Entering the digital health space in Germany

10th November @ 10:45AM EDT

Join us in this interactive masterclass led by Flying Health, as they discuss what you need to know to navigate the DiGa framework. Apply now to learn valuable insights from thought leaders in this space.

Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Len-Philipp Ortlepp
Len-Philipp Ortlepp
Junior Startup Relationship Manager, Flying Health
Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Len-Philipp Ortlepp
Len-Philipp Ortlepp
Junior Startup Relationship Manager, Flying Health

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Commercialisation models for Virtual Care in Respiratory Diseases

3rd November @ 11:45AM EDT

Join our Digital Health Meeting as we discuss commercialisation models for Virtual Care in Respiratory Diseases. Apply now to hear from fellow peers in this space and share your own thoughts and experiences on this topic.

Featuring
Peter Small
Peter Small
Chief Medical Officer, Hyfe
Caleb Bank
Caleb Bank
Product Marketing at NuvoAir
Featuring
Peter Small
Peter Small
Chief Medical Officer, Hyfe
Caleb Bank
Caleb Bank
Product Marketing at NuvoAir
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: How to get your DTx product reimbursed in the US?

4th November @ 11:45AM EDT

Are you a DTx company seeking reimbursement in the US? Then this masterclass is for you. Join us in this US-focused interactive masterclass led by Mike Pace, who will walk us through how to get your DTx product reimbursed in the US.

Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.